157 related articles for article (PubMed ID: 15592834)
41. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound.
Gerber B; Krause A; Müller H; Reimer T; Külz T; Makovitzky J; Kundt G; Friese K
J Clin Oncol; 2000 Oct; 18(20):3464-70. PubMed ID: 11032586
[TBL] [Abstract][Full Text] [Related]
42. Microwave endometrial ablation for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Zhu Y; Yang J
J Obstet Gynaecol Res; 2013 Sep; 39(9):1411-4. PubMed ID: 23815697
[TBL] [Abstract][Full Text] [Related]
43. Uterine effects of tamoxifen: a prospective study.
McGonigle KF; Smith DD; Marx HF; Morgan RJ; Vasilev SA; Roy S; Wong PT; Simpson JF; Wilczynski SP
Int J Gynecol Cancer; 2006; 16(2):814-20. PubMed ID: 16681767
[TBL] [Abstract][Full Text] [Related]
44. Prevalence of endometrial proliferation in pipelle biopsies in tamoxifen-treated postmenopausal women with breast cancer in Kuwait.
Al-Azemi M; Labib NS; Motawy MM; Temmim L; Moussa MA; Omu AE
Med Princ Pract; 2004; 13(1):30-4. PubMed ID: 14657616
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole.
Valenzano Menada M; Costantini S; Moioli M; Bogliolo S; Papadia A; Ferrero S; Dugnani MC
Breast; 2008 Dec; 17(6):631-6. PubMed ID: 18606545
[TBL] [Abstract][Full Text] [Related]
46. Apoptosis as a possible candidate mechanism for removal of tamoxifen-related endometrial cells with KRAS mutations.
Tsujioka H; Hachisuga T; Hikita S; Ueda T; Yotsumoto F; Shirota K; Yoshizato T; Kawarabayashi T; Kuroki M; Miyamoto S
Anticancer Res; 2010 Aug; 30(8):3119-23. PubMed ID: 20871029
[TBL] [Abstract][Full Text] [Related]
47. Hysteroscopic evaluation of the endometrium of post-menopausal patients with breast cancer before and after tamoxifen use.
Gonçalves MA; Gonçalves WJ; Matias MM; Nazario AC; de Lima GR; Baracat EC
Int J Gynaecol Obstet; 1999 Sep; 66(3):273-9. PubMed ID: 10580675
[TBL] [Abstract][Full Text] [Related]
48. Endometrial thickness and ovarian cysts as measured by ultrasound in asymptomatic postmenopausal breast cancer patients on various adjuvant treatments including tamoxifen.
Lindahl B; Andolf E; Ingvar C; Liedman R; Ranstam J; Willén R
Anticancer Res; 1997; 17(5B):3821-4. PubMed ID: 9427787
[TBL] [Abstract][Full Text] [Related]
49. Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium.
Mourits MJ; Hollema H; De Vries EG; Ten Hoor KA; Willemse PH; Van Der Zee AG
Hum Pathol; 2002 Mar; 33(3):341-6. PubMed ID: 11979376
[TBL] [Abstract][Full Text] [Related]
50. Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients.
Tepper R; Beyth Y; Altaras MM; Zalel Y; Shapira J; Cordoba M; Cohen I
Gynecol Oncol; 1997 Mar; 64(3):386-91. PubMed ID: 9062139
[TBL] [Abstract][Full Text] [Related]
51. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
O'Regan RM; Cisneros A; England GM; MacGregor JI; Muenzner HD; Assikis VJ; Bilimoria MM; Piette M; Dragan YP; Pitot HC; Chatterton R; Jordan VC
J Natl Cancer Inst; 1998 Oct; 90(20):1552-8. PubMed ID: 9790548
[TBL] [Abstract][Full Text] [Related]
52. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer.
Milla-Santos A; Milla L; Rallo L; Solano V
Breast Cancer Res Treat; 2001 Jan; 65(2):119-24. PubMed ID: 11261827
[TBL] [Abstract][Full Text] [Related]
53. Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens.
Cohen I; Altaras MM; Beyth Y; Shapira J; Figer A; Tepper R; Cordoba M; Yigal D; Bernheim J
Gynecol Oncol; 1997 Apr; 65(1):83-8. PubMed ID: 9103396
[TBL] [Abstract][Full Text] [Related]
54. Steroid receptor expression in endometria from women treated with tamoxifen.
Kommoss F; Karck U; Prömpeler H; Pfisterer J; Kirkpatrick CJ
Gynecol Oncol; 1998 Aug; 70(2):188-91. PubMed ID: 9740688
[TBL] [Abstract][Full Text] [Related]
55. Postmenopausal endometrial pathologies with tamoxifen treatment: comparison between hysteroscopic and hysterectomy findings.
Cohen I; Azaria R; Aviram R; Bernheim J; Tepper R; Cordoba M; Beyth Y
Gynecol Obstet Invest; 1999; 48(3):187-92. PubMed ID: 10545744
[TBL] [Abstract][Full Text] [Related]
56. Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer.
Wiseman LR; Goa KL
Drugs; 1997 Jul; 54(1):141-60. PubMed ID: 9211086
[TBL] [Abstract][Full Text] [Related]
57. Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Breast Cancer Res Treat; 2007 Jan; 101(2):185-90. PubMed ID: 16897434
[TBL] [Abstract][Full Text] [Related]
58. Antiestrogenic tamoxifen and toremifene increase serum leptin levels in postmenopausal breast cancer patients.
Marttunen MB; Andersson S; Hietanen P; Karonen SL; Koistinen HA; Koivisto VA; Tiitinen A; Ylikorkala O
Maturitas; 2000 May; 35(2):175-9. PubMed ID: 10924844
[TBL] [Abstract][Full Text] [Related]
59. Maturation of vaginal and endometrial epithelium in postmenopausal breast cancer patients receiving long-term tamoxifen.
Lahti E; Vuopala S; Kauppila A; Blanco G; Ruokonen A; Laatikainen T
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):410-4. PubMed ID: 7835781
[TBL] [Abstract][Full Text] [Related]
60. Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies.
Cohen I; Tepper R; Rosen DJ; Shapira J; Cordoba M; Dror Y; Altaras M; Beyth Y
Gynecol Oncol; 1994 Oct; 55(1):138-43. PubMed ID: 7959255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
